Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C37H48N4O5
CAS Number:
Molecular Weight:
628.80
UNSPSC Code:
12352200
NACRES:
NA.77
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -20 to -27°, c = 0.4 in methanol
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
SMILES string
N4(CCCNC4=O)[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@@H](NC(=O)COc3c(cccc3C)C)Cc2ccccc2)Cc1ccccc1
InChI
1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
InChI key
KJHKTHWMRKYKJE-SUGCFTRWSA-N
Application
Lopinavir has been used as a ZMPSTE24 and human immunodeficiency virus protease inhibitor.
Biochem/physiol Actions
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that normally metabolizes protease inhibitors. Lopinavir also has an ability to inhibit ZMPSTE24 (zinc metallopeptidase STE24).
Still not finding the right product?
Explore all of our products under Lopinavir
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Didier K Ekouevi et al.
BMC infectious diseases, 14, 461-461 (2014-08-27)
Few data are available on antiretroviral therapy (ART) response among HIV-2 infected patients. We conducted a systematic review on treatment outcomes among HIV-2 infected patients on ART, focusing on the immunological and virological responses in adults. Data were extracted from
H L Sham et al.
Antimicrobial agents and chemotherapy, 42(12), 3218-3224 (1998-12-03)
The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using the X-ray crystal structure of the complex of HIV protease
K A Sutherland et al.
The Journal of antimicrobial chemotherapy, 70(1), 243-248 (2014-09-18)
PI susceptibility results from a complex interplay between protease and Gag proteins, with Gag showing wide variation across HIV-1 subtypes. We explored the impact of pre-treatment susceptibility on the outcome of lopinavir/ritonavir monotherapy. Treatment-naive individuals who experienced lopinavir/ritonavir monotherapy failure
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML1222-10MG | 04061832636603 |
| SML1222-50MG | 04061837107696 |